Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Heinz Gisslinger(Medical University of Vienna), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Franz-Josef Tarmann(AOP Orphan (Austria)), Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Oleh Zahriychuk(AOP Orphan (Austria)), Richard Greil(Paracelsus Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Renate Schoder(Medical University of Vienna), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Sonja Burgstaller(Klinikum Wels-Grieskirchen), C. Wächter(AOP Orphan (Austria)), Róbert Královics(Medical University of Vienna)
Cited by 2
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450